CA3124499A1 - Method for treating parkinson's disease by administering resiniferatoxin - Google Patents

Method for treating parkinson's disease by administering resiniferatoxin Download PDF

Info

Publication number
CA3124499A1
CA3124499A1 CA3124499A CA3124499A CA3124499A1 CA 3124499 A1 CA3124499 A1 CA 3124499A1 CA 3124499 A CA3124499 A CA 3124499A CA 3124499 A CA3124499 A CA 3124499A CA 3124499 A1 CA3124499 A1 CA 3124499A1
Authority
CA
Canada
Prior art keywords
aav
rtx
vehicle
mice
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124499A
Other languages
English (en)
French (fr)
Inventor
Alexis Nahama
Henry Hongjun Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CA3124499A1 publication Critical patent/CA3124499A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3124499A 2018-12-24 2019-12-23 Method for treating parkinson's disease by administering resiniferatoxin Pending CA3124499A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784650P 2018-12-24 2018-12-24
US62/784,650 2018-12-24
US201962914170P 2019-10-11 2019-10-11
US62/914,170 2019-10-11
PCT/US2019/068235 WO2020139797A1 (en) 2018-12-24 2019-12-23 Methods for treating parkinson's disease by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
CA3124499A1 true CA3124499A1 (en) 2020-07-02

Family

ID=71126251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124499A Pending CA3124499A1 (en) 2018-12-24 2019-12-23 Method for treating parkinson's disease by administering resiniferatoxin

Country Status (8)

Country Link
US (1) US12201608B2 (https=)
EP (1) EP3902539B1 (https=)
JP (1) JP7519359B2 (https=)
KR (1) KR20210107086A (https=)
CN (1) CN113473983B (https=)
AU (1) AU2019414329A1 (https=)
CA (1) CA3124499A1 (https=)
WO (1) WO2020139797A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108979A (ko) 2018-12-21 2021-09-03 소렌토 쎄라퓨틱스, 인코포레이티드 부적응 통증을 치료하기 위한 레시니페라톡신의 신경 주위 투여
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
JP7530365B2 (ja) 2019-01-22 2024-08-07 ソレント・セラピューティクス・インコーポレイテッド レシニフェラトキシンを投与することによって変形性関節症疼痛を処置するための方法
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
WO2008109026A1 (en) 2007-03-05 2008-09-12 Mt Cook Pharma Pharmaceutical compositions for the localized treatment of neurogenic dysfunction
DK2222289T3 (da) * 2007-11-19 2013-10-07 Nestec Sa Behandling af oral pharyngeal dysphagi
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN105017155B (zh) * 2014-04-16 2017-06-16 华东师范大学 类三环二萜并吡唑衍生物及其制备方法和应用
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
CN107126445A (zh) * 2017-04-20 2017-09-05 江南大学 粪菌移植在治疗帕金森病方面的应用

Also Published As

Publication number Publication date
JP2022514695A (ja) 2022-02-14
US20210299090A1 (en) 2021-09-30
EP3902539B1 (en) 2024-07-31
CN113473983A (zh) 2021-10-01
EP3902539A4 (en) 2022-08-24
WO2020139797A1 (en) 2020-07-02
KR20210107086A (ko) 2021-08-31
EP3902539A1 (en) 2021-11-03
JP7519359B2 (ja) 2024-07-19
AU2019414329A1 (en) 2021-06-10
CN113473983B (zh) 2024-07-23
US12201608B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
US12201608B2 (en) Methods for treating Parkinson's disease by administering resiniferatoxin
KR100298808B1 (ko) 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
Kalkman et al. Effects of propofol, etomidate, midazolam, and fentanyl on motor evoked responses to transcranial electrical or magnetic stimulation in humans
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
PT1789433E (pt) Métodos de tratamento de vermelhidão cutânea usando agonistas selectivos do receptor adrenérgico alfa-2
RU2095060C1 (ru) Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний
Niu et al. Effect of bilateral deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease
Zou et al. Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats
JP2004521112A (ja) 関節痛治療薬を製造することへの神経毒性物質の使用
EP3057589B1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
Krilis et al. Vision loss and partial third nerve palsy following contralateral peribulbar anesthesia
Sarubbo et al. Five-year follow-up of 10 patients treated with globus pallidus internus deep brain stimulation for segmental or multisegmental dystonia
JPH07505608A (ja) インターロイキン−１阻害化合物による神経病学的状態の治療
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
Chang et al. Combined bilateral anterior cingulotomy and ventral capsule/ventral striatum deep brain stimulation for refractory obsessive-compulsive disorder with major depression: do combined procedures have a long-term benefit?
EP3016657B1 (en) Method for preventing and/or treating chronic traumatic encephalopathy-ii
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
US8633165B2 (en) Neuroprotective effects of 2DG in traumatic brain injury
KR101796923B1 (ko) 인삼 열매 추출물을 함유하는 퇴행성 신경장애 치료용 조성물
Schiff et al. FORCED CIRCLING MOVEMENTS (ADVERSIVE SYNDROME): Correction with Dinenhydrinate (Dramamine)
Lennox et al. The effect of benzedrine on the post-electroshock EEG
Udall Toxicology and the Nervous System: Drug-Induced Blindness in Some Experimental Animals and its Relevance to Toxicology
Urino et al. Epileptic focus stimulation and seizure control in the rat model of kainic acid-induced limbic seizures
CN115105520B (zh) 黄芩苷在制备用于治疗弱视的药物中的应用
Lawless Minocycline plus N-acetylcysteine improve chronic and progressive structural and functional deficits following a single TBI in male mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231219

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241209

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED

Effective date: 20250311

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204